Angiotensin Converting Enzyme

Type: Keyphrase
Name: Angiotensin Converting Enzyme
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Study Modification: Angioedema in response to angiotensin-converting enzyme inhibitor

AUTHOR: Pare GSTUDY DATE: July 8, 2013TITLE: Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. ... [Published National Human Genome Research Institute - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Hibiscus tea is shown to lower blood pressure

In the United States, high blood pressure is the most common medical condition.It has been estimated that one out of three Americans have high blood pressure. Untreated high blood pressure significantly increases the risk of stroke, heart attack and sudden ... [Published Chicago Daily Herald - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Blood Pressure-Lowering Peptides from Neo-Fermented Buckwheat Sprouts: A New Approach to Estimating ACE-Inhibitory Activity

by Masahiro Koyama, Seiji Hattori, Yoshihiko Amano, Masanori Watanabe, Kozo NakamuraNeo-fermented buckwheat sprouts (neo-FBS) contain angiotensin-converting enzyme (ACE) inhibitors and vasodilators with blood pressure-lowering (BPL) properties in spontaneously ... [Published Plosone.org - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

PARADIGM-HF: Is It Applicable to US Patients?

Hello. This is Ileana Piña, Associate Chief of Cardiology at Montefiore Einstein Hospital and Medical Center in the Bronx, New York. Today I am in the beautiful city of Barcelona at the European Society of Cardiology (ESC) Congress. More than 30,000 individuals ... [Published General Medicine eJournal - Sep 12 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Renin-Angiotensin System Blockade and Worsening Renal Function in Heart Failure An Unfinished Story ∗

Up to one-half of patients with heart failure (HF) have preserved ejection fraction (HFpEF). Although treatment of patients with HF and reduced ejection fraction (HFrEF) is well established and based on evidence from multiple randomized clinical trials, ... [Published Journal of the American College of Cardiology - Sep 08 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Example of Trial Design Data Relevant for All Stakeholders

BioCentury  has lead article this week “Betting Big on Hearts” by Emily Cukier-Meisner, Senior Writer, discussing a breakthrough drug for cardiovascular disease developed by Novartis. LCZ696 for heart failure will replace ACE inhibitors widely, so ... [Published eClinical Trends - Sep 08 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

Angiotensin-converting–enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials.1,2 Long-term treatment ... [Published NEJM Articles Most Widely Covered in the Press - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Incentivised case finding and other stories . . .

At its best, general practice can be a wonderful human interchange, carried out in short encounters over many years. At its worst, it can be like the dysfunctional processes described in a qualitative study ( BMJ Open 2014;4:e005146, doi:10.1136/bmjopen-2014-005146) ... [Published British Medical Journal - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 2 reports

Novartis may have game-changing drug

Share this article: Novartis is poised to change the way heart-failure patients are treated, if weekend reaction to data surrounding its experimental drug LCZ696 is any indication. The company released data at the European Society of Cardiology Congress ... [Published Medical Marketing And Media - Sep 03 2014]
First reported Aug 30 2014 - Updated Aug 30 2014 - 1 reports

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

Angiotensin-converting–enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials. Long-term treatment with ... [Published The New England Journal of Medicine: Cardiology - Aug 30 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Biolab offers CVD panel testing for genetic mutations

, the exclusive Biomnis dealer in the Kingdom, offers a Cardiovascular Disease CVD panel test for genetic mutations associated with blood clotting in the body, which is considered one of the latest tests in the diagnosis of heart disease.CVD Panel testing ... [Published Albawaba - Aug 25 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

BNF updates advice on dual blockade and ivabradine use

Source: Zayacskz / Dreamstime.comPatients taking ivabradine should be monitored for bradycardia (a resting heart rate below 60 beats per minute)Warnings on “dual blockade” — the concomitant use of drugs that affect the renin-angiotensin system (RAS) — ... [Published Pharmaceutical Journal - Aug 19 2014]

Quotes

Mark Hollis , CEO of MacPractice stated, "With this certification, we believe our customers, who prefer to use Macs and Apple native products in their practices, are well prepared to successfully demonstrate meaningful use."
...the definition of biomarkers since in 2001, a working group of the National Institutes of Health standardized the definition of a biomarker as a "characteristic that is objectively measured and established as an indicator of normal biological pathologic processes, pathogenetic processes, or pharmacologic responses to a therapeutic intervention" . A biomarker may be measured on a biosample (such as a blood test, for instance, the D-dimer as a biomaker of vulnerable blood) or it may be an imaging...
Sleep is a factor in blood pressure: "People with sleep apnea tend to have more high blood pressure, and treating it improves blood pressure modestly" he says
...poor prognosis for patients at risk for hospitalization, " said Sean E Harper, M D , executive vice president of Research and Development at Amgen. "Analyses from the pivotal SHIFT study complement the main trial findings that form the basis of our U S submission package for ivabradine. We recently received a priority review designation for ivabradine from the FDA and are working with the agency to potentially bring this important treatment option to certain patients with chronic heart failure in the U SS as soon as possible."

More Content

All (81) | News (68) | Reports (0) | Blogs (13) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
MacPractice MD MU Achieves ONC HIT 2014 Edition... [Published Ask.com - 3 hours ago]
Integrated Natriuretic Peptide and Echo-Guided ... [Published Theheart.org - 17 hours ago]
Study Modification: Angioedema in response to a... [Published National Human Genome Research Institute - Sep 17 2014]
SFRP5 Correlates With Obesity and Metabolic Syn... [Published General Medicine eJournal - Sep 17 2014]
When You Learn You Have High Blood Pressure [Published PR Web via Yahoo! - Sep 16 2014]
Vitamin D Deficiency Aggravates Chronic Kidney ... [Published Plosone.org - Sep 15 2014]
Blood Pressure-Lowering Peptides from Neo-Ferme... [Published Plosone.org - Sep 15 2014]
Hibiscus tea is shown to lower blood pressure [Published Chicago Daily Herald - Sep 15 2014]
Amgen Presents Analyses Of Phase 3 Ivabradine D... [Published Scottrade - Sep 15 2014]
Inhibiting Neprilysin Is Good for the Heart: Wh... [Published Alzheimer Research Forum - Sep 13 2014]
A Rapid-Fire Review of Four Big Trials From ESC... [Published Theheart.org - Sep 12 2014]
PARADIGM-HF: Is It Applicable to US Patients? [Published General Medicine eJournal - Sep 12 2014]
Parkinson's Disease Pharmacogenomics: New Findings [Published General Medicine eJournal - Sep 12 2014]
New Guidance for Managing Sickle Cell Disease [Published PT Community - Sep 10 2014]
FDA Advisors Say ‘No’ to Nebivolol/ Valsartan C... [Published PT Community - Sep 10 2014]
Renin-Angiotensin System Blockade and Worsening... [Published Journal of the American College of Cardiology - Sep 08 2014]
Example of Trial Design Data Relevant for All S... [Published eClinical Trends - Sep 08 2014]
Novartis' LCZ696: A New Paradigm For Heart Fail... [Published Seeking Alpha - Sep 08 2014]
FDA Approves 2 New Indications for Epaned®, the... [Published Pettinga Financial Advisors - Sep 08 2014]
Heart failure drug could 'cut deaths by a fifth' [Published Antrim Times - Sep 06 2014]
Medtronic : Patent Issued for Physiological Per... [Published 4 Traders - Sep 04 2014]
Researchers' Work from University of Gothenburg... [Published 4 Traders - Sep 04 2014]
NEJM Publishes Heart Failure Treatment History,... [Published Pharmacy Times - Sep 04 2014]
Novel heart failure therapy shows “overwhelming... [Published Pharmaceutical Journal - Sep 04 2014]
Paradigm Shifts in Heart-Failure Therapy — A Ti... [Published New England Journal of Medicine - Sep 04 2014]
Sacubitril - Valsartan, a "New Threshold of Hop... [Published Health Care Renewal - Sep 03 2014]
Angiotensin–Neprilysin Inhibition versus Enalap... [Published NEJM Articles Most Widely Covered in the Press - Sep 03 2014]
Incentivised case finding and other stories . . . [Published British Medical Journal - Sep 03 2014]
Novartis may have game-changing drug [Published Medical Marketing And Media - Sep 03 2014]
Combination of old and new drugs reduces CHF to... [Published American Council On Science & Health - Sep 02 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Example of Trial Design Data Relevant for All S... [Published eClinical Trends - Sep 08 2014]
BioCentury  has lead article this week “Betting Big on Hearts” by Emily Cukier-Meisner, Senior Writer, discussing a breakthrough drug for cardiovascular disease developed by Novartis. LCZ696 for heart failure will replace ACE inhibitors widely, so ...
Sacubitril - Valsartan, a "New Threshold of Hop... [Published Health Care Renewal - Sep 03 2014]
Summer must be over, because the next new blockbuster drug appears to be here.  At the end of August, the media heralded the results of a study of a new product for congestive heart failure (CHF) from Novartis. Novartis' New "Game Changer" The New York ...
Angiotensin–Neprilysin Inhibition versus Enalap... [Published NEJM Articles Most Widely Covered in the Press - Sep 03 2014]
Angiotensin-converting–enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials.1,2 Long-term treatment ...
Angiotensin–Neprilysin Inhibition versus Enalap... [Published The New England Journal of Medicine: Cardiology - Aug 30 2014]
Angiotensin-converting–enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials. Long-term treatment with ...
Could statins help treat Ebola? [Published AMERICAblog News| A great nation deserves the t ... - Aug 18 2014]
In an article in the New York Times , two physicians propose using drugs that are currently available to treat Ebola. Ebola causes a derangement in endothelial cells (cells lining blood vessels), and this can lead to decreased ability of the patient’s ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.